Do analysts rate RNAZ or IMNN?

Imunon has a consensus price target of $10.00, indicating a potential upside of 594.44%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, RNAZ or IMNN?

Imunon is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A Imunon N/A N/A -$14.49M -$3.83 N/A

Is RNAZ or IMNN more profitable?

Imunon's return on equity of -358.01% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% Imunon N/A -358.01% -132.91%

Does the media refer more to RNAZ or IMNN?

In the previous week, Imunon had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 4 mentions for Imunon and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.93 beat Imunon's score of 0.38 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, KYNB or IMNN?

Kyntra Bio has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 4.87 $183.45M $45.30 0.17 Imunon N/A N/A -$14.49M -$3.83 N/A

Is KYNB or IMNN more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Imunon's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% Imunon N/A -358.01% -132.91%

Does the media favor KYNB or IMNN?

In the previous week, Imunon had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 4 mentions for Imunon and 2 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.93 beat Imunon's score of 0.38 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CNTX or IMNN?

Context Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A Imunon N/A N/A -$14.49M -$3.83 N/A

Is CNTX or IMNN more profitable?

Context Therapeutics' return on equity of -82.06% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Imunon N/A -358.01% -132.91%

Does the media prefer CNTX or IMNN?

In the previous week, Imunon had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for Imunon and 3 mentions for Context Therapeutics. Imunon's average media sentiment score of 0.38 beat Context Therapeutics' score of 0.25 indicating that Imunon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Imunon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ATNM or IMNN more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Imunon N/A -358.01% -132.91%

Does the media prefer ATNM or IMNN?

In the previous week, Imunon had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Imunon and 1 mentions for Actinium Pharmaceuticals. Imunon's average media sentiment score of 0.38 beat Actinium Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Imunon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, IMNN or QNCX?

Imunon is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Imunon N/A N/A -$14.49M -$3.83 N/A Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A

Is IMNN or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -358.01% -132.91% Quince Therapeutics N/A N/A -133.84%

Imunon (IMNN) Competitors

$1.44 +0.04 (+2.86%)

As of 11:11 AM Eastern

Compare

IMNN vs. RNAZ, KYNB, CNTX, ATNM, and QNCX

Should you buy Imunon stock or one of its competitors? Imunon's main competitors and comparable companies include TransCode Therapeutics (RNAZ), Kyntra Bio (KYNB), Context Therapeutics (CNTX), Actinium Pharmaceuticals (ATNM), and Quince Therapeutics (QNCX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Imunon compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

In the previous week, Imunon had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 4 mentions for Imunon and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.93 beat Imunon's score of 0.38 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Imunon is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Imunon has a consensus price target of $10.00, indicating a potential upside of 594.44%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.5% of Imunon shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TransCode Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Imunon has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

Imunon's return on equity of -358.01% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
Imunon	N/A	-358.01%	-132.91%

Summary

Imunon beats TransCode Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Imunon compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Kyntra Bio has a net margin of 2,199.13% compared to Imunon's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Imunon	N/A	-358.01%	-132.91%

In the previous week, Imunon had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 4 mentions for Imunon and 2 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.93 beat Imunon's score of 0.38 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.87	$183.45M	$45.30	0.17
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kyntra Bio presently has a consensus target price of $36.00, indicating a potential upside of 364.46%. Imunon has a consensus target price of $10.00, indicating a potential upside of 594.44%. Given Imunon's higher possible upside, analysts clearly believe Imunon is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kyntra Bio has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Imunon has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Summary

Kyntra Bio beats Imunon on 12 of the 15 factors compared between the two stocks.

How does Imunon compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Imunon had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for Imunon and 3 mentions for Context Therapeutics. Imunon's average media sentiment score of 0.38 beat Context Therapeutics' score of 0.25 indicating that Imunon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Context Therapeutics' return on equity of -82.06% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Imunon	N/A	-358.01%	-132.91%

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Context Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Imunon has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

Context Therapeutics presently has a consensus target price of $6.17, suggesting a potential upside of 1,544.44%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 594.44%. Given Context Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Context Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Context Therapeutics beats Imunon on 8 of the 13 factors compared between the two stocks.

How does Imunon compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Actinium Pharmaceuticals has a beta of 0.05, meaning that its stock price is 95% less volatile than the broader market. Comparatively, Imunon has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

Actinium Pharmaceuticals' return on equity of -100.85% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Imunon	N/A	-358.01%	-132.91%

Imunon has lower revenue, but higher earnings than Actinium Pharmaceuticals. Imunon is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	1.12	-$48.82M	$0.36	3.49
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Actinium Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 298.41%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 594.44%. Given Imunon's higher possible upside, analysts clearly believe Imunon is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Imunon had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Imunon and 1 mentions for Actinium Pharmaceuticals. Imunon's average media sentiment score of 0.38 beat Actinium Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Imunon beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Imunon compare to Quince Therapeutics?

Imunon (NASDAQ:IMNN) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Imunon has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

4.5% of Imunon shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 2.8% of Imunon shares are owned by insiders. Comparatively, 5.6% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Quince Therapeutics' return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-358.01%	-132.91%
Quince Therapeutics	N/A	N/A	-133.84%

Imunon is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Imunon presently has a consensus price target of $10.00, suggesting a potential upside of 594.44%. Quince Therapeutics has a consensus price target of $260.00, suggesting a potential upside of 842.92%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42

In the previous week, Imunon had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 4 mentions for Imunon and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.87 beat Imunon's score of 0.38 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Imunon	Neutral
Quince Therapeutics	Very Positive

Summary

Quince Therapeutics beats Imunon on 9 of the 14 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNN vs. The Competition

Export

Metric	Imunon	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.16M	$3.84B	$7.20B	$14.98B
Dividend Yield	N/A	3.65%	2.57%	11.71%
P/E Ratio	-0.38	14.09	273.78	25.46
Price / Sales	N/A	1,434.00	700.09	112.52
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	0.63	15.30	10.44	6.22
Net Income	-$14.49M	-$22.78M	$3.49B	$358.21M
7 Day Performance	-4.64%	-0.51%	-0.29%	0.15%
1 Month Performance	-12.73%	0.57%	-0.07%	-3.29%
1 Year Performance	-73.43%	39.31%	19.14%	6.49%

Imunon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNN Imunon	3.3605 of 5 stars	$1.44 +2.9%	$10.00 +594.4%	-74.9%	$8.16M	N/A	N/A	30
RNAZ TransCode Therapeutics	0.5896 of 5 stars	$1.89 -8.3%	N/A	-85.4%	$34.88M	N/A	N/A	9	Gap Up
KYNB Kyntra Bio	3.4583 of 5 stars	$8.22 -3.9%	$36.00 +338.0%	N/A	$34.62M	$4.62M	0.18	570
CNTX Context Therapeutics	2.9496 of 5 stars	$0.38 +4.0%	$6.17 +1,538.8%	-55.1%	$33.23M	N/A	N/A	7
ATNM Actinium Pharmaceuticals	1.6932 of 5 stars	$1.23 +19.4%	$5.00 +306.5%	-22.8%	$32.38M	$35.09M	N/A	30	News Coverage Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNN) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Imunon (IMNN) Competitors

IMNN vs. RNAZ, KYNB, CNTX, ATNM, and QNCX

How does Imunon compare to TransCode Therapeutics?

Summary

How does Imunon compare to Kyntra Bio?

Summary

How does Imunon compare to Context Therapeutics?

Summary

How does Imunon compare to Actinium Pharmaceuticals?

Summary

How does Imunon compare to Quince Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Imunon (IMNN) Competitors

IMNN vs. RNAZ, KYNB, CNTX, ATNM, and QNCX

How does Imunon compare to TransCode Therapeutics?

Does the media refer more to RNAZ or IMNN?

Which has stronger earnings and valuation, RNAZ or IMNN?

Do analysts rate RNAZ or IMNN?

Do insiders and institutionals have more ownership in RNAZ or IMNN?

Which has more volatility and risk, RNAZ or IMNN?

Is RNAZ or IMNN more profitable?

Summary

How does Imunon compare to Kyntra Bio?

Is KYNB or IMNN more profitable?

Does the media favor KYNB or IMNN?

Which has better earnings & valuation, KYNB or IMNN?

Do institutionals and insiders hold more shares of KYNB or IMNN?

Do analysts rate KYNB or IMNN?

Which has more risk and volatility, KYNB or IMNN?

Summary

How does Imunon compare to Context Therapeutics?

Does the media prefer CNTX or IMNN?

Which has stronger earnings & valuation, CNTX or IMNN?

Is CNTX or IMNN more profitable?

Do insiders & institutionals hold more shares of CNTX or IMNN?

Which has more volatility & risk, CNTX or IMNN?

Do analysts rate CNTX or IMNN?

Summary

How does Imunon compare to Actinium Pharmaceuticals?

Which has more risk & volatility, ATNM or IMNN?

Is ATNM or IMNN more profitable?

Which has stronger valuation and earnings, ATNM or IMNN?

Do analysts rate ATNM or IMNN?

Does the media prefer ATNM or IMNN?

Do institutionals & insiders have more ownership in ATNM or IMNN?

Summary

How does Imunon compare to Quince Therapeutics?

Which has more volatility and risk, IMNN or QNCX?

Do institutionals & insiders hold more shares of IMNN or QNCX?

Is IMNN or QNCX more profitable?

Which has preferable earnings & valuation, IMNN or QNCX?

Do analysts prefer IMNN or QNCX?

Does the media prefer IMNN or QNCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools